컨퍼런스 커버리지 | 학술센터 | 킴스온라인

주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기

최근 해외학술대회의 주요 발표내용을 제공합니다.

컨퍼런스 커버리지

European Academy of Dermatology and Venereology (EADV) Congress 2025

17 September - 20 September, 2025, France

Denifanstat reduces lesions in acne vulgaris

2025-11-03

The fatty acid synthase inhibitor denifanstat shows potential for treating moderate-to-severe acne vulgaris, with good safety and tolerability, as demonstrated in a study from China presented at EADV 2025.
GLP-1RA offers protection against mortality, cardiac events for psoriasis patients

2025-11-03

Patients with psoriasis who are using glucagon-like peptide-1 receptor agonists (GLP-1RAs) appear to have lower risks of mortality and adverse cardiovascular events, according to a retrospective study.
Delgocitinib cream works wonders in chronic hand eczema

2025-11-03

Application of delgocitinib cream results in significant improvements in itch, pain, and quality of life (QoL) at week 16 in adults with moderate to severe chronic hand eczema (CHE), as shown in the pooled analysis of the phase III DELTA-1 and -2 trials.
Pooled data support ruxolitinib cream for prurigo nodularis treatment

2025-11-03

Twice-daily application of ruxolitinib cream led to early and sustained improvement in the signs and symptoms of prurigo nodularis in adults, according to the pooled phase III TRuE-PN1 and TRuE-PN2 studies presented at EADV 2025.
Extended-release minoxidil pill promotes hair growth in 4 months

2025-11-03

In patients with androgenetic alopecia, 4 months of treatment with the investigational extended-release oral minoxidil (VDPHL01) appears to induce superior hair growth compared with 6 months of treatment with the topical and immediate-release (IR) formulations, according to the results of a blinded retrospective Investigator Global Assessment (IGA) analysis.
Ritlecitinib efficacy sustained up to 3 years in ALLEGRO trials

2025-11-03

Ritlecitinib 50 mg demonstrates clinically meaningful efficacy up to 36 months in individuals with alopecia areata (AA) in the phase IIb/III ALLEGRO and ongoing phase III ALLEGRO-LT trials.
Rocatinlimab delivers in ROCKET-SHUTTLE trial

2025-11-03

Findings from the phase III ROCKET-SHUTTLE trial support the treatment potential of rocatinlimab for atopic dermatitis (AD).
Deucravacitinib delivers long-term efficacy in psoriatic arthritis

2025-11-03

Treatment with deucravacitinib demonstrates its superiority to placebo across several endpoints in patients with psoriatic arthritis (PsA) at week 16, according to the phase III POETYK PsA-2 study. Clinical responses have also persisted for up to a year.

1

최근 본 콘텐츠

최근 본 콘텐츠가 없습니다

TOP

주식회사 킴스

주식회사 킴스 | 광고/제휴문의 | 이용약관 | 개인정보처리방침 | 법적 책임의 한계 | 서비스 전체보기

서울특별시 강남구 테헤란로 8길 33 청원빌딩 1층 (주)킴스
개인정보관리책임자 : 최동섭 사업자등록번호 : 214-81-75415 통신판매업신고 : 강남-5166호 대표이사 : 마사키 타카하타
고객센터 : 1544-2930 (10:00~17:00, 주말/공휴일 제외) 팩스 : 02-3019-9380 e-mail : webmaster@kims.co.kr

Copyright © 1987-2025 KIMS Co., Ltd All Rights Reserved

KIMS 페이스북

KIMS 유튜브